Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T13:35:26.165Z.
Calculation as of: 2026-10-06T13:35:26.165Z.
Quote observation: 2026-10-06T13:33:17.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ca6b3f945453907090b614e1109f6f6fce8b12406cb587c45253d0481e46e17d
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $34.65M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.85M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $33.42M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.55M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.68M | 0.86 | 1.13 | 1.13 | 1.13 |
| BeyondSpring Inc. (BYSI)vs › | $32.12M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.37M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $37.13M | N/A | 241.49 | 241.49 | 115.68 |
| Context Therapeutics Inc. (CNTX)vs › | $31.39M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $29.91M | N/A | 876.90 | 876.90 | 876.90 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.60
Forward EPS (Est.)
$-6.30
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
